Navigation Links
CutisPharma Announces Issuance of a Patent for Suppository Compounding

US patent for the preparation, storage, and dispensing of compounded suppositories

WOBURN, Mass., Nov. 6 /PRNewswire/ -- CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,434,690) regarding a container and kit for the preparation, storage and dispensing of compounded suppositories.

"By its very nature, the process of compounding suppositories is cumbersome, time-consuming and in general, without adequate compensation" said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our container (suppository mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy. Our suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient dispensing tools", he added.

Currently CutisPharma has FIRST(R) Progesterone Vaginal Suppository Unit-of-Use Prescription Compounding Kit product line available, which uses the patented container. The line includes FIRST(R) - Progesterone VGS 25, 50, 100, 200 and 400 representing various strengths (mg.). The kits are made for a single patient and include pre-weighed progesterone, and suppository base, and the patented disposable container/mold for preparation, storage, and dispensing of the suppositories. A single NDC number assigned for the entire kit aids the third party reimbursement process, reduces audit- related adjustments, and the use of these FIRST(R) kits facilitates compliance with USP Chapter <795>. This patented container, kit, and the method will also be used for future suppository compounding kits such as Boric Acid, Morphine, and others.

CutisPharma estimates that over 1.5 million progesterone suppository prescriptions are written in the U.S. annually, representing a potential of nearly $100 million at the retail level. The Kit allows a pharmacy an easy entry into this market. The Company is experiencing a steady conversion from the conventional way to the FIRST(R) - way.

FIRST(R) products save dispensing time, are easy to use, and can be compounded by the pharmacist while the patient waits increasing customer satisfaction. Using FIRST(R) VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared by the traditional method using a metal suppository mold or polystyrene shells.

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at

SOURCE CutisPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
2. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
3. Stereotaxis Announces New Management Appointment
4. SXC Health Solutions announces third quarter financial results
5. 360 Healthcare Staffing Announces Agreement With BlueSky Medical Staffing Software
6. Cardinal Health Announces Preliminary Shareholder Voting Results at Annual Meeting
7. Dialysis Corporation of America Announces $25 Million Credit Facility
8. Cornerstone Therapeutics Announces New Board of Directors
9. CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results
10. BD Announces Executive Appointments of President and Chief Financial Officer
11. BD Announces Results for Fourth Fiscal Quarter and Full Year
Post Your Comments:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: